Glycoconjugate inhibition of Streptococcus pyrogenes adhesion

• US 5,401,723 A
• Filed: 12/02/1992
• Issued: 03/28/1995
• Est. Priority Date: 12/02/1992
• Status: Expired due to Fees

• Current Assignee: Colgate-Palmolive Company, Forsyth Dental Cente
• Original Assignee: Colgate-Palmolive Company, Forsyth Dental Center
• Inventors: Tylewska, Stanislawa, Gibbons, Ronald, Gaffar, Abdul
• Primary Examiner(s): Witshyn, Michael G.
• Assistant Examiner(s): SAYALA, CHHAYA D
• Application Number:
  US07/984,441
• Time in Patent Office: 846 Days
• Field of Search: 514/21, 514/54, 536/55.1, 536/55.2, 536/55.3, 525/54.1, 424/49
• US Class Current: 424/464
• CPC Class Codes: A61K 2800/57 Compounds covalently linked to a(n inert) carrier molecule, e.g. conjugates, pro-fragrances
• CPC Class Codes: A61K 47/643 Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
• CPC Class Codes: A61K 8/60 Sugars; Derivatives thereof
• CPC Class Codes: A61K 8/64 Proteins; Peptides; Derivatives or degradation products thereof
• CPC Class Codes: A61Q 11/00 Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses

Abstract

Enhancement of the method and oral compositions for inhibiting adherence of Streptococcus pyogenes to pharyngeal and oral mucosa cells by treating these areas with a glycoconjugate comprising an oligosaccharide linked to a carrier. The oligosaccharide should have at least one fucose moiety or a galatose moiety which is free of digalactose and N-acetylneuraminyl lactose. The carrier may include albumins, starch or synthetic polymers.

Claims

1. A method of inhibiting adherence of Streptococcus pyogenes to epithelial pharyngeal and oral cells comprising contacting said cells in the oral cavity with an oligosaccharide which is conjugated to a protein, a synthetic polymer or starch.

4. The method of claims 1, 2 or 3 wherein the oligosaccharide contains at least one fucose moiety or a galactose moiety which is free of N-acetylneuraminyl lactose.

5. The method of claims 1, 2 or 3 wherein the protein is an albumin.

6. The method of claims 1, 2 or 3 wherein the oligosaccharide is selected from the group consisting of A-tetrasaccharide, B'"'"'-sialyllactose, lacto-N-tetraose, B-trisaccharide, fucosyllactose, lacto-N-neotetraose and gangliotetraose, and the oligosaccharide is conjugated to human serum albumin or bovine serum albumin.

7. The method of claims 1, 2 or 3 wherein the oligasaccharide--conjugate is Gal 1-3 Gal N-acetyl-Human Serum Albumin, lacto-N-fucopentaose 1,1,1--Human Serum Albumin, Galbeta 1-4 galactose N-acetyl beta 1-0-para amino phenyl Human Serum Albumin.

9. The oral composition of claim 6 wherein the orally acceptable vehicle comprises a mouthrinse, mouthwash, toothpaste, chewing gum or lozenge.

11. The composition of claim 6 wherein the oligosaccharide is selected from the group consisting of A-tetrasaccharide, B'"'"'-sialyllactose, lacto-N-tetraose, B-trisaccharide, fucosyllactose, lacto-N-neotetraose and gangliotetraose, and the oligosaccharide is conjugated to human serum albumin or bovine serum albumin.

2. A method of preventing or treating a sore throat caused by Streptococcus pyogenes comprising applying to the soft mucosal surface of the throat an oligosaccharide which is conjugated to a protein, a synthetic polymer or starch which inhibits the adherence of said bacteria to said surface.

3. A method of inhibiting the adherence of Streptococcus pyogenes to the oral or pharyngeal mucosa comprising applying a oligosacchride which is conjugated to a protein, a synthetic polymer or starch thereto.

8. An oral composition comprising an orally acceptable vehicle and an oligosaccharide which is conjugated to a protein, a synthetic polymer or starch, the oligosaccaride-conjugate being in an amount to effectively inhibit the adherence of Streptococcus pyogenes to oral or pharyngeal mucosa or the cells thereof.

10. The composition of claim 8 wherein the oiigosaccharide contains at least one fucose moiety or a galactose moiety which is free of N-acetylneuraminyl lactose.

12. The composition of claim 8 wherein the oligosaccharide--conjugate is Gal 1-3 Gal N-acetyl-Human Serum Albumin, lacto-N-fucopentaose 1,1,1-Human Serum Albumin, Galbeta 1-4, galactose N-acetyl beta 1-0-para amino phenyl Human Serum Albumin.

13. The composition of claim 8 wherein the synthetic polymer is polyacrylic acid, polymethacrylic acid, polyvinylmethyl ether/maleic acid, polyacrylamide or polystyrene.